Multigene Mutation Analysis of Metastatic Lymph Nodes in Non-small Cell Lung Cancer Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

摘要: Background The importance of biomarker analysis in patients with non-small cell lung cancer (NSCLC) is well known. purpose this study was to analyze the mutation status multiple genes metastatic lymph nodes obtained by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and examine correlation between treatments outcomes. Methods Genetic alterations were analyzed hilar or mediastinal diagnosed EBUS-TBNA 156 NSCLC. Epidermal growth factor receptor ( EGFR ) using peptide nucleic acid-locked acid polymerase chain reaction clamp method (n = 156). V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog K-ras (exons 2-3) tumor protein 53 p53 4-8) direct sequencing 113). In addition, retrospective chart review performed for clinical data analysis. Results gene mutations detected 42 cases (26.9%). Twenty-three received gefitinib, an overall response rate (partial [PR]) 54.5% disease control (PR + stable disease) 86.4% (Response Evaluation Criteria Solid Tumors). four (3.5%), 47 (41.6%). Fifty-two underwent conventional chemotherapy (46 platinum-based chemotherapy). Patients showed chemoresistance (progressive 42.9%, P .0339) a relatively poor prognosis after .1391). Conclusions Multigene can be samples from allows genetic evaluation cells within node, which may allow physicians better select treatments, particularly tyrosine kinase inhibitors.